Clinical Performance of Bioglass‐Enriched Resin Modified Glass Ionomer in Sealing Moderate Carious Lesions: An 18‐Month Split‐Mouth Clinical Trial | Synapse
April 17, 2026Open Access
Clinical Performance of Bioglass‐Enriched Resin Modified Glass Ionomer in Sealing Moderate Carious Lesions: An 18‐Month Split‐Mouth Clinical Trial
Key Points
To assess the performance of bioglass-enriched resin modified glass ionomer (RMGIC) in sealing moderate carious lesions.
Conducted an 18-month split-mouth clinical trial
Compared retention and restoration quality between bioglass-enriched and standard RMGIC
Monitored caries progression and arrestment levels over time
No significant changes in retention between bioglass-enriched RMGIC and standard RMGIC
Restoration quality remained consistent across both materials
Caries progression and arrestment levels did not differ after 18 months
Abstract
The addition of 45S5 bioglass to RMGIC did not change the retention, restoration quality, and caries progression or arrestment levels after 18 months of follow-up.